The cardiovascular effects of naloxone 15 (ig/kg following morphine 2.0 mg/kg were studied in closed-chest dogs during light nitrous oxide-halothane anaesthesia. The bolus injection of naloxone caused an increase in heart rate (73%), cardiac output (20%) and mean arterial pressure (20%). Total peripheral resistance was unaffected. LV dP/dr max and LV dP/dr max/IP increased by 25% and 14% respectively, but positive inotropic effects could not be shown when load data, heart rate and the decrease in left ventricular ejection fraction (22%) were taken into consideration. The cardiovascular stimulation resulted in an increase in myocardial oxygen demand (66%) which was met by an increase in coronary blood flow (59%). The data suggest that the antagonism of narcotics with high doses of naloxone may impair the myocardial oxygen supply in patients suffering from coronary insufficiency. It is concluded that naloxone should be titrated for each patient to ensure adequate reversal of respiratory depression and to avoid circulatory stress.
Recent studies by Lowenstein and others (1969) , Wong and others (1973) , Samuel and Dundee (1975) and Stoelting and others (1975) demonstrated that high doses of narcotics did not cause major cardiovascular depression in normal man. Therefore large doses of narcotic analgesics are used frequently as sole anaesthetic agents, especially for patients requiring open heart surgery, and are used increasingly as supplements to anaesthesia. Depending on the amount of narcotics used and the elapsed time from the last dose, this technique may result in a profound respiratory depression, generally necessitating mechanical ventilatory support until the narcotics are metabolized. Alternatively, a narcotic antagonist may be used.
Since the synthesis of naloxone in 1960 by Lewenstein and Fishman (Blumberg, Dayton and Morris, 1961) , several investigators have studied its effect following narcotic-nitrous oxide anaesthesia for the purpose of antagonizing unwanted narcoticinduced respiratory depression (Hasbrouck, 1971; Longnecker, Grazis and Eggers, 1973; Heisterkamp and Cohen, 1974; Johnstone et al., 1974; Stephen, Cooper and Harvey, 1976) . However, little attention has been focused upon the simultaneous cardiovascular response. observations of tachycardia and hypertension (Huse, Hartung and Nadjmabadi, 1974; Tanaka, 1974; Freye, 1975 ) the purpose of this experimental study was to evaluate the response of haemodynamics, myocardial inotropism, coronary blood flow and the metabolic demand of the heart to naloxone in antagonizing morphine-nitrous oxide anaesthesia in dogs.
METHODS
The experiments were performed in six healthy unpremedicated mongrel dogs of either sex ranging in weight from 26 to 32 kg. Anaesthesia was induced with piritramide 2.0 mg/kg (Dipidolor, Janssen) i.v. and, after endotracheal intubation, anaesthesia was maintained with halothane 0.5% in a mixture of oxygen in nitrous oxide with controlled ventilation using an Engstrom respirator set at a frequency of 12/min. The minute volume, and the inspired Po 2 , were adjusted to maintain Pa C02 at 5.3 kPa and Pa Oz at 13.3 kPa approximately. If metabolic acidosis developed during the preparation or blood-gas data deviated from the normal, sodium bicarbonate was administered or the respirator settings were altered as appropriate. The base deficit never exceeded 6mmol/litre. Under fluoroscopic control, catheters were inserted into the right atrium, descending aorta, pulmonary artery and the left ventricle via the brachial and femoral vessels and then connected to pressure transducers (Statham P 23 Db), thus enabling us to measure the matching pressure values. Left ventricular pressure was measured using a catheter-tip micromanometer (Milar PC 350) which was passed from the femoral artery. The rate of increase (LV dP/dt) was obtained by differentiating the left ventricular pressure signal using a Statham SP 1400 amplifier and an RC differentiating circuit. Myocardial blood flow (CBF) was measured continuously by the pressure difference technique as described by Hensel and Bretschneider (1970) . The reference pressure catheter was inserted into the right external jugular vein; its tip was advanced into the coronary sinus and fixed in position with a fluid-filled cuff. Oxymetry and the blood flow contours confirmed the position of the catheter in the coronary sinus.
All pressure values, LV dPjdt, coronary blood flow and e.c.g. derived from standard limb leads were recorded continuously on a multichannel recorder (Hellige EK 21).
Cardiac output was measured using the thermodilution technique (Slama and Piiper, 1964) . The thermodilution curves were recorded and integrated with the cardiac output computer BN 6560 (Fischer, Gottingen). Arterial and coronary vein blood was sampled intermittently to determine the oxygen saturation and the haemoglobin content using a COOxymeter (Instrument-Laboratories, model 182). The end-systolic volume per 100 g of the left ventricle (ESV) was calculated using the formula for approximation (Bretschneider et al., 1972) :
where SAP = systolic aortic pressure (mm Hg) Stroke volume was calculated as the ratio of cardiac output and heart rate. Assuming that the blood flow in the coronary sinus represents only 75% of the left ventricular perfusion (Heiss et al., 1973) , the measured coronary sinus blood flow was calculated for 100%. This value was related to 100 g of the left ventricle, the weight of which was determined after sacrifice of the animals following completion of the study. The myocardial oxygen consumption (LV Vo 2 ) was derived from the product of coronary blood flow and the arterio-coronary venous oxygen content difference, the latter being calculated from oxygen saturation differences of the arterial and coronary venous blood and the haemoglobin concentration using the value 1.34 ml/g for the oxygen-combining capacity of haemoglobin. The preload independent index of myocardial contractility LV dPjdt max/IP (Veragut and Krayenbuehl, 1965; Prys-Roberts et al., 1972) After the induction of anaesthesia, approximately 2 h elapsed for surgical preparation and the catheterization of the vessels. Under light halothane anaesthesia with controlled ventilation the experimental animals received morphine 2.0 mg/kg i.v. and were then allowed to achieve a steady cardiovascular state over a period of 45 min. After control measurements were commenced naloxone (Narcan) 15.0 (xg/kg was given as an i.v. bolus. The haemodynamic responses to naloxone were followed for 10 min. Statistical comparisons were made using Student's t test for paired observations. Statistical significance was denned as P equal to or less than 0.05. The control values are presented as mean ± SEM.
RESULTS
A tracing from a typical experiment illustrates the cardiovascular response to naloxone in antagonizing morphine anaesthesia ( fig. 1 ). There was an increase in heart rate, systemic arterial pressure, coronary blood flow, cardiac output and peak LV dP/dt. The onset of action started immediately after the i.v. injection of naloxone and the maximum effect (1st min) was still apparent 5 min later. A return to the control values did not occur over the period of observation (10 min).
The maximum changes in haemodynamic variables following the administration of naloxone are presented in figures 2, 3 and 4. In the group of six animals the heart rate increased by an average of 73% (P< 0.005) of the control value of 96 + 6 beat/min, in parallel with an increase in cardiac index (control: 94.7 ± 9.6 ml. coronary blood flow (control: 58 + 6 ml. min" 1 per 100 g) by 59% (P<0.01), in arterio-venous oxygen content difference of the heart (control: 15.4 + 0.8 vol%) by 4% (P< 0.005), and in myocardial oxygen consumption (control: 8.7 + 0.7 ml.min" 1 per 100 g) by 66% (/ > <0.01). The coronary vascular resistance decreased by an average of 23% (P< 0.005) of the control value of 2.1 + 0.2mmHg. ml" 1 per 100 g ( fig. 4) .
DISCUSSION
Narcotic antagonists have been employed clinically for a variety of purposes: the treatment of known or suspected opiate poisoning (Evans, 1973; Waldron, 1973) , the diagnosis of narcotic addiction (Fraser, 1957) and the management of respiratory depression induced by narcotics (Eckenhoff and Oesch, 1960) . Since the narcotic antagonists used previously, levallorphan and nalorphine, possess also dosedependent agonist properties, there was a pressing need for a new narcotic antagonist free from undesirable side-effects. Naloxone, being 10-20 times more active than nalorphine and 3-6 times more active than levallorphan (Jasinski, Martin and Haertzen, 1967) in therapeutic doses, does not cause respiratory depression or exhibit any other agonist action. Therefore, it is considered to be the specific narcotic antagonist of choice for clinical use. The reversal of respiratory depression after the clinical administration of naloxone has been studied on several occasions (Hasbrouck, 1971; Longnecker, Grazis and Eggers, 1973; Johnstone et al., 1974) . Only a few reports, however, have described the cardiovascular response to naloxone. In a study of 40 surgical patients who were not premedicated with narcotics, Foldes, Duncalf and Kuwabara (1969) observed that 5 (xg/kg of naloxone had only insignificant effects on the circulation. When administered to non-narcotized conscious dogs or anaesthetized dogs, this narcotic antagonist was found to cause no circulatory change (Freye, 1974) . However, there is one report of a paradoxical hypertensive episode following its administration (Tanaka, 1974) . In a more detailed study Huse, Hartung and Nadjmabadi (1974) demonstrated that, in neurosurgical patients receiving neuroleptanalgesia, a single dose of naloxone 0.4 mg produced an increase in heart rate of 38%, in cardiac output of 44% and in arterial pressure of 35%. Freye (1974) investigated the haemodynamic response to naloxone 0.4 mg/kg given following increasing doses of fentanyl 0.0025-0.16 mg/kg in dogs and observed increases in heart rate, arterial pressure, LV dP/dt and in myocardial oxygen consumption up to 100% as compared with control values. However, these experiments were performed on dogs in whom thoracotomy had been performed and whose coronary sinus blood flow has been exteriorized through a 14-gauge catheter of relatively high flow resistance permitting only intermittent readings. No cardiac output measurements were made. Furthermore, the dose of naloxone used seems to be excessive.
In our experiments the cardiovascular response to naloxone in antagonizing morphine was studied in closed-chest dogs. The pressure difference technique allowed continuous readings of the coronary blood flow and the cardiac output was determined frequently. The following reports led us to choose a dose of 15 (i.g/kg of naloxone for an i.v. bolus injection following an administration of morphine 2.0 mg/kg: formerly the manufacturer recommended a dose of 0.4-0.8 mg of naloxone to be given initially (this has been changed recently to 0.1-0.2 mg); Longnecker, Grazis and Eggers (1973) showed antagonism of morphine 1.4 mg/kg with naloxone 15(ig/kg (5 fig/kg i.v. plus 10jig/kg i.m.); and Johnstone and others (1974) reported that the Wong team (1973) recommended an average of 40 fi-g/kg of naloxone in divided doses to antagonize morphine 2.0 mg/kg. The dose of 2.0 mg/kg of morphine is frequently used as the sole anaesthetic agent for high risk patients undergoing cardiac surgery (Lowenstein et al., 1969) and has been used for cardiovascular studies on human volunteers (Wong et al., 1973) .
The data of the present study demonstrated that the dose of naloxone investigated led to a stimulation of the cardiovascular system. In spite of the decrease in stroke volume (29%) the increase in heart rate by 73% resulted in an increase in cardiac output and, consequently, moderate hypertension, indicating that the systemic vascular resistance remained unaffected. Although the increase in the inotropic parameter, peak LV dPjdt, and the preload independent index of myocardial contractility, LV dP/dt max/IP, by 25% and 14% respectively could suggest positive inotropic effects, the increase in arterial pressure (20%) and cardiac output (20%) was not attributable to improved myocardial contractility. Taking load data and heart rate into consideration, the changes in LVdP/dt max and LV dPjdt max/IP were mainly the consequence of tachycardia and of increases in preload and afterload (Wallace, Skinner and Mitchell, 1963) . The reduction of left ventricular ejection fraction suggests even slight myocardial depression. Since halothane is generally thought to impair cardiac performance (Prys-Roberts et al., 1972) , the low control values of LV dP/dt max, LV dP/dt max/IP and of EF were probably a result of the halothane anaesthesia.
Heart rate, arterial systolic pressure, ejection time and velocity of myocardial contraction are the main determinants of the metabolic demands of the heart (Sonnenblick, Ross and Braunwald, 1968; Braunwald, 1971; Bretschneider, 1971) . Therefore tachycardia, hypertension and the increase in LV dP/dt max following the administration of naloxone led to an increase in myocardial oxygen consumption (66%) in parallel with an increase in coronary blood flow (59%). Although the widening of the coronary arterio-venous oxygen content difference was statistically significant, indicating that the metabolic demand of the heart was not met adequately by the increase in coronary blood flow and that additional oxygen utilization was necessary, the change in coronary arterio-venous oxygen difference of 4% is believed to be clinically insignificant if similar changes occur in man.
There is presumptive evidence that cardiovascular stimulation occurs also following the antagonism of other narcotics. Circulatory effects similar to those described above were found under identical experimental conditions in dogs narcotized with fentanyl 0.03 mg/kg ( fig. 5) .
The possible mechanism for these haemodynamic responses is not clear. Freye (1974) believes that naloxone in the presence of high doses of narcotics competes for identical receptor sites in the central nervous system and thus the "low dose effect" of narcotics becomes apparent. The author postulates that narcotics at low doses increase adrenergic activity as a result of catecholamine release from the adrenal medulla (Vassalle, 1961; Klingman and Maynert, 1962; Fennessy and Rattray, 1971) , while high doses are not associated with this response. Since the cardiovascular effects reported above were similar to those seen after the abrupt withdrawal of narcotics, a more likely interpretation is an "overshoot reaction" associated with an acute abstinence syndrome (Wikler, Fraser and Isabell, 1953; Martin, 1967) . Therefore, the data of the present study suggest that the dose of 15 (ig/kg of naloxone given as a single injection was in excess. Although naloxone in inappropriate doses can reduce the analgesic effect of narcotics, the haemodynamic reaction seen in our experiments was probably not mediated reflexly by stress or pain, as the experimental animals were anaesthetized with nitrous oxide and halothane.
The following conclusions could be drawn from the present study: A single i.v. bolus injection of naloxone for the complete or partial antagonism of narcotic depression after operation should not be administered, since excessive doses of naloxone may initially antagonize analgesia and may result in discomfort and also in circulatory stress. Although such cardiovascular stimulation may be tolerated in patients with normal myocardial and coronary vascular function, in those who suffer from coronary insufficiency a careful titration with increments of naloxone should be employed to avoid an unbalanced ratio between myocardial oxygen demand and supply. In these patients the intrinsic autoregulatory mechanisms of the coronary blood flow are impaired and the coronary blood flow depends mainly on a linear pressure-flow relationship. Since our experiments demonstrated that the increase in metabolic requirements of the heart exceeded the increase in coronary perfusion pressure three-fold, a tissue metabolic-perfusion mismatching and, consequently, anaerobic glycolysis may occur. 
SUMARIO
Los efectos cardiovasculares de naloxona 15 |xg/kg tras morfina 2,0 mg/kg fueron estudiados a torax cerrado en los perros durante anestesia ligera con monoxido de nitrogenohalotano. La inyeccion de bolo naloxona causo un aumento en la frequencia cardiaca (73%), gasto cardiaco (20%) y presion arterial media (20%). La resistencia total periferica no se vio afectada. LV dPjdt max y LV dP/dr max/PI (PI = presion developada instantemente en el ventriculo izquierdo) aumentaron en el 25% y 14 % respectivamente, pero no pudieron demostrarse efectos inotropicos positivos cuando se tomaron en consideration los datos de sobrecarga, frecuencia cardiaca y descenso de la fraction de eyeccion ventricular izquierda (22%). La estimulacion cardiovascular result6 en un aumento de la demanda de oxigeno miocardico (66%) que fue satisfecha mediante un aumento del flujo hematico coronario (59%). Los datos sugieren que el antagonismo de los narcoticos con altas dosis de naloxona pudiera afectar el aporte de oxigeno miocardico en pacientes aquejados de insuficiencia coronaria. Se concluye que la naloxona debiera ser titulada para cada paciente para asegurar una inversion adecuada de la depresion respiratoria y evitar el stress circulatorio.
